Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Nagy A. Farid"'
Autor:
Nagy A. Farid, Kenneth J. Winters, Joseph R. Walker, Fanni Natanegara, Joseph A. Jakubowski, Ronan P. Kelly, Lei Shen, David S. Small, Sandra L Close, Mary Ho
Publikováno v:
British Journal of Clinical Pharmacology. 73:93-105
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Observations from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjec
Autor:
David S. Small, C. Steven Ernest, Kenneth J. Winters, Nagy A. Farid, Shashank Rohatagi, Christopher D. Payne, John H. April, Ying G. Li, Lan Ni
Publikováno v:
The Journal of Clinical Pharmacology. 51:321-332
An integrated analysis of pharmacokinetic (PK) parameter estimates for prasugrel, from 16 phase I clinical pharmacology studies, consolidated exposure estimates from 506 healthy male and female participants and evaluated the effect of specific intrin
Publikováno v:
The Journal of Clinical Pharmacology. 50:126-142
Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine-5'-diphosphate (ADP)-mediated platelet aggregation in vivo. These compounds are converted to thiol-containing active metabolites through a corresponding thiola
Autor:
Fanni Natanegara, Mei Teng Loh, Eunice Yuen, Daniel E. Salazar, Ronan M. Kelly, Molly Tomlin, Christopher D. Payne, Prajakti A. Kothare, D. Richard Lachno, Joseph A. Jakubowski, Kenneth J. Winters, Ying G. Li, Lan Ni, David S. Small, Nagy A. Farid
Publikováno v:
Clinical Therapeutics. 32:365-379
Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is
Autor:
Miho Kazui, Osamu Okazaki, Nagy A. Farid, Katsunobu Hagihara, Atsushi Kurihara, Kokichi Honda, Toshihiko Ikeda, Michiharu Yoshiike
Publikováno v:
Drug Metabolism and Disposition. 37:2145-2152
The efficiency and interindividual variability in bioactivation of prasugrel and clopidogrel were quantitatively compared and the mechanisms involved were elucidated using 20 individual human liver microsomes. Prasugrel and clopidogrel are converted
Autor:
Nagy A. Farid, Kenneth J. Winters, David S. Small, C. Steven Ernest, Christopher D. Payne, Daniel E. Salazar, Ying G. Li
Publikováno v:
Current Medical Research and Opinion. 24:2251-2257
Clopidogrel is an oral thienopyridine antiplatelet agent indicated for the treatment of atherothrombotic events in patients with acute coronary syndrome (ACS). Prasugrel, a novel oral thienopyridine, is under investigation for the reduction of athero
Autor:
David S. Small, Ying G. Li, Kenneth J. Winters, Nagy A. Farid, Daniel E. Salazar, Govinda Weerakkody, Christopher D. Payne, John T. Brandt
Publikováno v:
The Journal of Clinical Pharmacology. 48:475-484
Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y(12) ADP receptor. In this open-label, 4-period crossover study, the effects of the proton pump inhibitor lansoprazole on t
Autor:
Eric T. Williams, Steven A. Wrighton, G. Douglas Ponsler, Everett J. Perkins, Nagy A. Farid, Shane M. Lowery, Miho Kazui, Kenneth J. Ruterbories, Karen O. Jones
Publikováno v:
Drug Metabolism and Disposition. 36:1227-1232
2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (prasugrel) is a novel thienopyridine prodrug with demonstrated inhibition of platelet aggregation and activation. The biotransformation of prasugrel to it
Autor:
Katsunobu Hagihara, Toshihiko Ikeda, Miho Kazui, Atsushi Kurihara, Yumi Nishiya, Nagy A. Farid
Publikováno v:
Drug Metabolism and Pharmacokinetics. 23:412-420
Differences in the inhibition of cytochrome P450 activities among thienopyridine antiplatelet agents, ticlopidine, clopidogrel, prasugrel, and the metabolites, 2-oxo-clopidogrel, clopidogrel acid metabolite, deacetylated metabolite of prasugrel (R-95
Autor:
David S Small, Ying G. Li, Christopher D. Payne, Joseph A. Jakubowski, John T. Brandt, Nagy A. Farid, Daniel E. Salazar, Kenneth J. Winters
Publikováno v:
Thrombosis and Haemostasis. 99:409-415
SummaryVariability in response to antiplatelet agents has prompted the development of point-of-care (POC) technology. In this study, we compared theVerifyNowTM P2Y12 (VN-P2Y12) POC device with light transmission aggregometry (LTA) in subjects switche